Avacta Group Plc · LSE:AVCT
Avacta — Shareholder Meeting (July 2025)
18 slides from Avacta's shareholder meeting presentation, Jul 2, 2025
Slide 1: Expanding the reach of highly potent cancer therapies
Expanding the reach of highly potent cancer therapies Annual General Meeting July 2, 2025
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding the Company’s research, preclinical and clinical development activities, plans and projected timelines for AVA6000 and the Avacta pipeline, plans re
Slide 3: Highlights and Achievements
Highlights and Achievements
Slide 4: Progress Against Strategic Objectives
Progress Against Strategic Objectives FAP-Dox (AVA6000) – The first pre|CISION program • Completed Phase 1a enrollment dose escalation portion of clinical trial • Opening of Phase 1b expansion cohorts - anticipate releasing initial data in salivary gland cancer in late 2025 and triple negative breas
Slide 5: Management Team Strengthened
Management Team Strengthened David Liebowitz. PhD Yulii Bogatyrenko Chief Medical Officer Advisor, Business Development David is a hematologist-oncologist with more than 30 years of industry Yulii is a Principal at Biopharma C&I, a biotechnology experience across academia and industry, including bio
Slide 6: FAP-Dox: Recent Case of a Second Partial Response in a Patient with Salivary Gland Cancer
FAP-Dox: Recent Case of a Second Partial Response in a Patient with Salivary Gland Cancer Baseline Cycle 2 (March 2025) (June 2025) Case Study: This patient is a 69 year old male with recent diagnosis of R. Lung metastatic salivary gland cancer. lesion His prior therapy for localized disease include
Slide 7: Leveraging AI to Predict the Most Sensitive Tumor Types to AVA6103
Leveraging AI to Predict the Most Sensitive Tumor Types to AVA6103 Will Increase the Probability of Success in Phase 1 • Higher tumor expression of SLFN11 predicts sensitivity to the Topoisomerase I inhibitor mechanism of action • To predict indications with strong probability of response to AVA6103
Slide 8: Biomarker Driven Trials Enhance Our Understanding of Efficacy in Phase 1 Trials
Biomarker Driven Trials Enhance Our Understanding of Efficacy in Phase 1 Trials Ph I data Trial continues only SLFN11 positive in SLFN11 positive Phase 1 enrollment gated only by cancer indication Measure FAP and SLFN11 Ph I data SLFN11 negative • Assume that higher SLFN11 predicts for favorable res
Slide 9: Computational Algorithms Predict pre|CISION Medicine Features in the Clinic
Computational Algorithms Predict pre|CISION Medicine Features in the Clinic Ten pre|CISION warheads have been designed and characterized both Computational algorithms are used to design novel pre|CISION in vitro and in vivo informed by the FAP docking model. Together these data medicines in conjunct
Slide 10: pre|CISION: Three IP Families Align with the Product Pipeline
pre|CISION: Three IP Families Align with the Product Pipeline Avacta holds an enviable IP position with multiple families and new foundational IP around the sustained release mechanism of pre|CISION delivery Details of programs cannot be disclosed prior to filing the IP pre|CISION® Platform Foundati
Slide 11: Challenges
Challenges
Slide 12: Financial Challenges
Financial Challenges • Heights Convertible Bond • Inherited bond with onerous terms (raised to fund the purchase of the diagnostics businesses) • Actively looked at numerous options including debt refinancing, debt for equity swap, restructuring – all too onerous for existing shareholders or not pos
Slide 13: Next Chapter
Next Chapter
Slide 14: Avacta: Upcoming Key Data Catalysts 2025-2026
Avacta: Upcoming Key Data Catalysts 2025-2026 FAP-Dox (Program 1) FAP-EXd (Program 2) Pipeline Program 3 Data Catalysts Data Catalysts Data Catalyst FAP-Dox (AVA6000) advances to FAP-EXd (AVA6103) file the IND in Identify third pipeline program expansion cohorts (Phase 1b) late 2025 and initiate dos
Slide 15: Opportunities Created by Multiple Catalysts in 2025-2026
Opportunities Created by Multiple Catalysts in 2025-2026 ▪ Demonstrated clinical proof of concept: significant operational progress over the past year as the pre|CISION® platform achieved proof of concept in the clinic, with significant reduction in key toxicities and evidence of efficacy presented
Slide 16: Thank You
Thank You © AVACTA LIFE SCIENCES LIMITED 2024
Slide 17: Avacta SP Performance vs. UK Small Cap Oncology Companies
Avacta SP Performance vs. UK Small Cap Oncology Companies UK Oncology small cap peers (n=13) traded on Nasdaq with share price performance plotted since March 2024 17
Slide 18: The Avacta Board of Directors Strengthened with Two New NEDs
The Avacta Board of Directors Strengthened with Two New NEDs Shaun Chilton Mark Goldberg, MD Paul Fry Richard Hughes David Bryant Chairman of the Board Non-Executive Director Non-Executive Director Non-Executive Director Non-Executive Director Shaun Chilton was formerly CEO Mark is an oncologist on